A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Optiray
Synonyms :
ioversol
Class :
Non-ionic iodinated contrast media
Brand Name :
Optiray
Synonyms :
ioversol
Class :
Non-ionic iodinated contrast media
Dosage Forms & Strengths
Injectable solution
160mg/mL-34%
240mg/mL-51%
300mg/mL-64%
320mg/mL-68%
350mg/mL-74%
Cerebral Arteriography
Use 51%, 64% or 68%
2-12 mL for carotid or vertebral arteries; Do not exceed Maximum dose of 200 mL
20-50 mL for aortic arch injection; Do not exceed Maximum dose of 200 mL
Peripheral Arteriography
Use 64%, 68% or 74%
60 mL (range 20-90 mL) for aorta-iliac runoff; Do not exceed Maximum dose of 250 mL
40 mL (range 10-50 mL) for common iliac, femoral; Do not exceed Maximum dose of 250 mL
20 mL (range 15-30 mL) for subclavian, brachial; Do not exceed Maximum dose of 250 mL
Coronary Arteriography
Use 68% or 74%
8 mL (range 2-10 mL) for left coronary; Do not exceed Maximum dose of 250 mL
6 mL (range 1-10 mL) for right coronary; Do not exceed Maximum dose of 250 mL
40 mL (range 30-50 mL) for left ventricle; Do not exceed Maximum dose of 250 mL
Use 51%, 64%, 68%, and 74% for head and body imaging
Head Imaging
Note: After the intravenous infusion is finished, scan right away
51%: 100-250 mL (Infusion)
64%: 50-150 mL (Infusion)
68%: 50-150 mL (Infusion)
74%: 50-150 mL (Infusion)
Body Imaging
Note: The scanning interval varies depending on the indication and target organ.
51%: 35-100 mL (Bolus Injection) 70-250 mL (Infusion)
64%: 25-75 mL (Bolus Injection) 50-150 mL (Infusion)
68%: 320 25-75 mL (Bolus Injection) 50-150 mL (Infusion)
74%: 350 25-75 mL (Bolus Injection) 50-150 mL (Infusion)
Dosage Forms & Strengths
Injectable solution
160mg/mL-34%
240mg/mL-51%
300mg/mL-64%
320mg/mL-68%
350mg/mL-74%
Use 68% for Head and Body Imaging
1.5-2 mL/kg (range 1-3 mL/kg)
Use 74% or 68%
1.25 mL/kg (range 1 mL/kg-1.5 mL/kg)
Do not exceed 5 mL/kg up to a maximum total volume of 250 mL
Use 74% or 68%
1.25 mL/kg (range 1 mL/kg-1.5 mL/kg)
Do not exceed 5 mL/kg up to a maximum total volume of 250 mL
Refer to adult dosing
may increase the adverse effect of metformin
they decrease the efficacy of sodium iodide I-131 iodinated contrast agents
they decrease the efficacy of sodium iodide I-131 iodinated contrast agents
they decrease the efficacy of sodium iodide I-131
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
the interaction may increase the risk of nephrotoxicity and ototoxicity
May have an increased hypersensitivity or allergic reactions when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
Iodinated Contrast Agents may increase the adverse/toxic effect of Metformin
they increase the toxicity of saxagliptin/metformin
Actions and Spectrum:
ioversol is a contrast agent used in imaging studies, such as computed tomography (CT) scans and magnetic resonance imaging (MRI). Its actions include:
The spectrum of ioversol includes:
Frequency Defined
<1%
Arrhythmia
Tinnitus
Vertigo
Vision blurred
Conjunctivitis
Atrioventricular block complete
Periorbital edema
Vomiting
Hematoma
Abdominal pain
Myocardial infarction
Extravasation
Angina pectoris
Rhinitis
Injection site hematoma
Vascular pseudoaneurism
muscle spasms
Acidosis
Black Box Warning
The black box warning for ioversol states that it should not be used in patients with severe renal impairment or in those who are at risk for renal failure. This is because ioversol can cause damage to the kidneys, which can lead to renal failure.
Contraindication/Caution:
Ioversol is contraindicated in individuals who have known hypersensitivity to ioversol or any of its components. It is also contraindicated in patients with severe uncontrolled hypertension, severe cardiac disease, or severe hepatic or renal dysfunction.
Ioversol should be used with caution in patients with moderate to severe hypertension, mild to moderate cardiac disease, mild to moderate hepatic or renal dysfunction, or in patients with a history of allergies or asthma. It should also be used with caution in pregnant or breastfeeding women.
Patients should be closely monitored for adverse reactions and possible changes in vital signs during and after ioversol administration. If any serious reactions occur, the administration of ioversol should be discontinued immediately.
Pregnancy warnings:
AU TGA pregnancy category: B1
US FDA pregnancy category: B
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
ioversol, also known as isovue, is a nonionic, water-soluble contrast agent used in X-ray and CT imaging procedures to enhance the visibility of internal structures. It is made up of an iodine compound that is highly opaque to X-rays and can be used to help differentiate between normal and abnormal tissue. Pharmacodynamics:
Pharmacodynamics of ioversol include:
Overall, the pharmacodynamics of ioversol are designed to improve the visualization of blood vessels and organs during imaging procedures, while also being safe and well-tolerated.
Pharmacokinetics:
Absorption
ioversol is rapidly and completely absorbed following intravenous injection.
Distribution
ioversol is primarily distributed in the vascular compartment, with a volume of distribution of approximately 200-300 mL/kg. It does not readily cross the blood-brain barrier or the placenta.
Metabolism
ioversol is not metabolized and is excreted unchanged in the urine.
Elimination and excretion
ioversol has a half-life of approximately 2 hours and Excreted through Urine (>95%)
Administration:
Intravenously (IV) Administered
Administration of ioversol is typically done intravenously (IV) through a vein in the arm or hand. The dosage and duration of administration will depend on the specific imaging procedure being performed and the patient’s individual needs.
Prior to administration, the healthcare provider will typically perform a thorough medical history and physical examination, including a review of any allergies or previous reactions to contrast agents. Patients may also be pre-medicated with medications such as antihistamines or steroids to reduce the risk of an allergic reaction.
During the procedure, the healthcare provider will carefully monitor the patient for any adverse reactions. If a reaction occurs, appropriate treatment will be provided immediately.
After the procedure, patients will typically be advised to drink plenty of water to help flush the contrast out of their system and to report any unusual symptoms to their healthcare provider.
It is important to note that ioversol should not be used in patients with known allergies to iohexol or other iodinated contrast agents. It should also not be used in patients with severe renal impairment or anuria. Patients should discuss any concerns or questions with their healthcare provider prior to administration.
Patient information leaflet
Generic Name: ioversol
Why do we use ioversol?
ioversol is used as a contrast agent in imaging studies, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), to enhance the visibility of blood vessels, organs, and other structures in the body. The use of ioversol allows radiologists to see details that may not be visible on plain X-ray images. This helps to distinguish between normal and abnormal tissue and facilitates the diagnosis of a wide range of conditions, including:
Overall, ioversol is an important tool in imaging and diagnosis of various medical conditions, it allows for accurate diagnosis and treatment planning.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
